Sensus Healthcare (NASDAQ:SRTS) was downgraded by research analysts at B. Riley from a “buy” rating to a “neutral” rating in a report released on Thursday, MarketBeat reports. They currently have a $5.50 price target on the stock, down from their previous price target of $14.00. B. Riley’s price objective would indicate a potential upside of 44.74% from the stock’s current price.
Several other analysts also recently weighed in on the stock. Maxim Group set a $11.00 target price on shares of Sensus Healthcare and gave the company a “buy” rating in a report on Friday, August 9th. ValuEngine downgraded shares of Sensus Healthcare from a “buy” rating to a “hold” rating in a report on Thursday, October 17th. TheStreet upgraded shares of Sensus Healthcare from a “d+” rating to a “c-” rating in a report on Monday, August 26th. Finally, HC Wainwright reiterated a “buy” rating and issued a $10.00 target price on shares of Sensus Healthcare in a report on Thursday. One investment analyst has rated the stock with a sell rating, three have given a hold rating and four have issued a buy rating to the company’s stock. The company has a consensus rating of “Hold” and an average target price of $8.30.
Sensus Healthcare stock traded down $0.21 during midday trading on Thursday, reaching $3.80. The company had a trading volume of 73,900 shares, compared to its average volume of 31,014. The firm’s fifty day simple moving average is $5.73 and its 200-day simple moving average is $5.72. The company has a market capitalization of $93.54 million, a P/E ratio of -27.14 and a beta of -0.41. Sensus Healthcare has a 12-month low of $3.71 and a 12-month high of $9.23.
A number of institutional investors have recently bought and sold shares of the stock. Essex Investment Management Co. LLC acquired a new stake in Sensus Healthcare in the 3rd quarter valued at approximately $540,000. Susquehanna International Group LLP grew its stake in shares of Sensus Healthcare by 69.9% in the second quarter. Susquehanna International Group LLP now owns 27,492 shares of the company’s stock worth $152,000 after acquiring an additional 11,311 shares in the last quarter. BlackRock Inc. grew its stake in shares of Sensus Healthcare by 40.7% in the second quarter. BlackRock Inc. now owns 103,643 shares of the company’s stock worth $574,000 after acquiring an additional 29,990 shares in the last quarter. Heartland Advisors Inc. grew its stake in shares of Sensus Healthcare by 150.0% in the second quarter. Heartland Advisors Inc. now owns 375,000 shares of the company’s stock worth $2,078,000 after acquiring an additional 225,000 shares in the last quarter. Finally, Wells Fargo & Company MN acquired a new position in shares of Sensus Healthcare in the second quarter worth $30,000. Hedge funds and other institutional investors own 9.95% of the company’s stock.
About Sensus Healthcare
Sensus Healthcare, Inc manufactures and markets superficial radiation therapy devices to healthcare providers worldwide. It offers SRT-100, a photon X-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers; and SRT-100 Vision, which provides the user with a superficial radiation therapy-tailored treatment planning application that integrates the embedded high frequency ultrasound imaging module, volumetric tumor analysis, beam margins planning, and dosimetry parameters.
Featured Article: Moving Average (MA)
Receive News & Ratings for Sensus Healthcare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sensus Healthcare and related companies with MarketBeat.com's FREE daily email newsletter.